On November 6, the FDA approved daratumumab and hyaluronidase-fihj for adults with high-risk smoldering multiple myeloma. For more information, read the FDA announcement and the Janssen Biotech press release.
On November 6, the FDA approved daratumumab and hyaluronidase-fihj for adults with high-risk smoldering multiple myeloma.
For more information, read the FDA announcement and the Janssen Biotech press release.
Posted on 11/7/2025
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
